Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alka-Seltzer Plus line extension

This article was originally published in The Tan Sheet

Executive Summary

New Alka-Seltzer Plus Nose & Throat backed by TV ad featuring tagline "totally focused relief," as well as Nov. 3 FSI drop, in-store displays, Bayer says. Ad campaign, designed by BBDO (Chicago), broke in October. On shelves now, Nose & Throat contains four active ingredients - acetaminophen 250 mg, chlorpheniramine maleate 2 mg, dextromethorphan hydrobromide 10 mg, phenylephrine hydrochloride 5 mg - to provide "more comprehensive relief of your worst cold symptoms," such as runny nose, nasal congestion, sore throat and cough. Effervescent tablets are available in citrus blend flavor; 20-count box retails for roughly $5.99. Also, Bayer has brought back "classic seltzer flavor" for Alka-Seltzer Plus Cold; revamped taste hit shelves in October...
Advertisement

Related Content

Bayer Focuses On OTCs As Consumer Care Streamlining Continues

Topics

Advertisement
UsernamePublicRestriction

Register

PS094746

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel